Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Automatic Data Processing

Emerson Electric

Federal Realty Investment Trust

General Dynamics

Lowe's

Altria

Parker-Hannifin

Raytheon Technologies

Stanley Black & Decker

T. Rowe Price Group

Last week the S&P 500 had its best week since 1974, roaring higher by 12%. That defies the mounting economic damage the US is facing and plummeting earnings expectations.

The 13 Best Dividend Aristocrats To Buy In This Uncertain Economy

Vanguard Dividend Appreciation ETF

Abbott Labs

Colgate-Palmolive

CVS Health

Johnson & Johnson

Microsoft

NIKE

PepsiCo

QUALCOMM

Texas Instruments

Walgreens

Walmart

I hold 15 Dividend Achievers. That index is available in ETF form by way of Vanguard's Dividend Appreciation Fund - ticker VIG.

My Dividend Achievers Quarterly Review. More Than Up To The Investment Challenge Of COVID-19

Eli Lilly

Johnson & Johnson (NYSE:JNJ), Medtronic PLC (NYSE:MDT) and Eli Lilly and Co (NYSE:LLY) are strong performers, as their share prices have increased more than the S&P 500 index over the past several years.

This Trio of Strong Performers Is Predicted to Outperform

PetIQ

PETQ vs. MDT: Which Stock Is the Better Value Option?

PETQ vs. MDT: Which Stock Should Value Investors Buy Now?

The iPhone assembler and the medical device company are teaming up to "fast track" production at the controversial factory.

Foxconn works with Medtronic to make ventilators at its Wisconsin plant

Medtronic Plc MDT, +5.10% said late Wednesday it has received an OK from the U.S.

Medtronic gets emergency authorization to sell compact ventilator in the U.S. by May.

DUBLIN, April  08, 2020  (GLOBE NEWSWIRE) --     Medtronic plc   (NYSE:MDT), the global leader in medical technology, today announced updates regarding its efforts to increase ventilator production around the globe. The company is announcing solid progress in the ramp-up of its ventilator production, as well as collaborating with technology partners and governments to drive new ventilator innovation and production, all in support of COVID-19 patients worldwide.

Medtronic Provides Ventilator Progress Update

Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.

Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns

Ford Motor Company

ResMed

In a world hit hard by the coronavirus, ventilator stocks could enrich shareholders while the companies are potentially saving lives.

3 Ventilator Stocks to Buy for the Coronavirus Crisis

Ball

The COVID-19 pandemic has taken the U.S. economy from near-record-low unemployment to mass layoffs and firings.

Deep Dive: Three stocks to buy during the coronavirus crash — besides the usual suspects

Target

These dividend stocks are ideal for risk-averse investors looking for some recurring income.

3 Dividend Aristocrats You Can Buy Today at a Discount

General Electric

General Motors

Hill-Rom Hlds

Trump—amid criticism from both sides—has thus far only used the act sparingly.

Trump Ordered These Companies To Make Medical Supplies Under The Defense Production Act

Medtronic sells in-demand ventilators, which are needed to treat the coronavirus. Medtronic stock should rise as a result.

Weakness in Medtronic Stock Is Creating a Major Opportunity

With national stockpile inventory of life-saving healthcare equipment getting dangerously close to zero, President Trump signaled that he will leverage a key national security provision to order additional companies to produce ventilators. Trump’s reluctance to employ the law known as the Defense Production Act (DPA) has puzzled many as the administration attempts to right the […]

White House says it is ordering more companies to make ventilators

Cardinal Health

COVID-19 has increased the demand for ventilators and personal protective equipment, which can aid these three companies at large.

3 Must-Buy Stocks as Coronavirus Cases Spike (Revised)

Aflac

A. O. Smith

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Chubb

Dover

Ecolab

Genuine Parts

McDonald's

McCormick

Nucor

In times of market turmoil, one group of stocks that investors can count on to deliver reliable income growth is the Dividend Aristocrats: an elite group of companies that have produced at least 25 consecutive years of dividend hikes.

19 Dividend Aristocrats That Have Gone on Deep Discount

Tesla

The company is sharing specifications for a basic model with any company that wants to help produce them for hospitals racing to treat coronavirus patients

Medtronic Gives Away Ventilator Design Specs In Coronavirus Fight, Ahead Of Tesla Alliance

Healthcare and biomedical engineering company Medtronic, which was in the news recently because Tesla CEO Elon Musk had discussions with the company about the automaker’s potential plans to build ventilator hardware in order to , but today it’s doing something potentially far more impactful. Medtronic is making the full design specifications, produce manuals, design documents, […]

Medtronic is sharing its portable ventilator design specifications and code for free to all

Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.

Medtronic's Evolut TAVR System Shows Positive Study Results

The medical device maker is giving the schematics and software away free so that other manufacturers can help address the shortage of portable ventilators.

Medtronic Makes Plans for a Ventilator Open-Source

3 Must-Buy Stocks as Coronavirus Cases Spike

First  S tudy in the U.S. and Japan to Report Results on One-Month DAPT Duration in High Bleeding Risk Patients with Current-Generation DES

Medtronic Onyx ONE Clear Study of One-Month Dual-Antiplatelet Therapy in High Bleeding Risk Stent Patients Beats Performance Goal

DUBLIN, March  30, 2020  (GLOBE NEWSWIRE) --     Medtronic plc   (NYSE:MDT), the global leader in medical technology, today announced it is publicly sharing the design specifications for the Puritan Bennett™ 560 (PB 560) to enable participants across industries to evaluate options for rapid ventilator manufacturing to help doctors and patients dealing with COVID-19. This decision is consistent with the recent  FDA Guidance  and in accordance with the public health and medical response of governmental agencies globally.

Medtronic Shares Ventilation Design Specifications to Accelerate Efforts to Increase Global Ventilator Production

ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication 

Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure

News for Medtronic Stock (MDT)